Loading clinical trials...

The Role of Inflammation in Ocular Tumours | Clinical Trials | Clareo Health

UNKNOWN

The Role of Inflammation in Ocular Tumours

NCT02909517•Unity Health Toronto

Summary

This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: 1. Choroidal nevus 2. Choroidal indeterminate melanocytic lesion 3. Choroidal melanoma 4. Suspected metastatic tumour (ie, primary tumour elsewhere) 5. Locally treated ocular tumours

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Any tentative clinical diagnosis of:
•1. Choroidal nevus (low-risk features):
•2. Choroidal indeterminate melanocytic lesion (high-risk features)
•3. Choroidal melanoma
•4. Suspected metastatic tumour (ie, primary tumour elsewhere)
•5. Locally treated ocular tumours
•Note that a patient can enroll in this study twice, once before treatment and once after, provided that at least one month has passed since initiation of treatment. This patient will count twice (ie, once in each of two study arms)
•Male and female age 18 years and older Ability to provide informed consent

Exclusion Criteria

•Allergy to angiography dye
•Cases that do not meet the above criteria for tumor size will be ineligible to participate in the study.
•Patients not able to provide consent for the study.
•Patients with a poor view of the fundus due to cataract or vitreous hemorrhage.
•Patients \< 18 years of age. Any concurrent unrelated eye diagnosis

Locations (2)

St Michael's Hospital

Toronto, Ontario, Canada

Princess Margaret Cancer Centre, Ontario

Toronto, Ontario, Canada

Key Dates

Start Date

March 1, 2016

Primary Completion Date

May 1, 2020

Completion Date

May 1, 2020

Last Updated

May 23, 2019

Enrollment

ESTIMATED participants

Conditions

Ocular Melanoma

Interventions

cSLO imaging

OTHER

Contacts

Emily Mathieu, PhD

CONTACT

4168646060 mathieue@smh.ca

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690

Choroidal MelanomaIndeterminate Lesions+2 more

View study

RECRUITINGPHASE1/PHASE2

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

NCT07136181

Metastatic Uveal MelanomaUveal Melanoma, Metastatic+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Role of Inflammation in Ocular Tumours

Inclusion Criteria

Exclusion Criteria

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Adjuvant Melatonin for Uveal Melanoma

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Neoadjuvant and Adjuvant Checkpoint Blockade

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye